[Neuroprotection. Bases and possibilities of a future clinical use].
Lagrèze
W A
WA
D000316:Adrenergic alpha-Agonists / Q000627:therapeutic use; D000818:Animals; D017209:Apoptosis / Q000187:drug effects / Q000502:physiology; D000068438:Brimonidine Tartrate; D002986:Clinical Trials as Topic; D004195:Disease Models, Animal; D015259:Dopamine Agents / Q000627:therapeutic use; D005128:Eye Diseases / Q000188:drug therapy* / Q000503:physiopathology; D005544:Forecasting; D005901:Glaucoma / Q000188:drug therapy; D006801:Humans; D008559:Memantine / Q000627:therapeutic use; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D009902:Optic Neuritis / Q000188:drug therapy; D011810:Quinoxalines / Q000627:therapeutic use; D012164:Retinal Diseases / Q000503:physiopathology; D014794:Visual Fields
D000316:Adrenergic alpha-Agonists; D015259:Dopamine Agents; D018696:Neuroprotective Agents; D011810:Quinoxalines; D000068438:Brimonidine Tartrate; D008559:Memantine